✦ LIBER ✦

Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: A phase 2 study

✍ Scribed by Hillary A. Hahm; Deborah K. Armstrong; Ting-Ling Chen; Louise Grochow; Jose Passos-Coelho; Steven N. Goodman; Nancy E. Davidson; M.John Kennedy

Book ID: 117727863
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 158 KB
Volume: 6
Category: Article
ISSN: 1083-8791
DOI: 10.1016/s1083-8791(00)70059-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

536 High dose medroxyprogesterone acetat

536 High dose medroxyprogesterone acetate (MPA)in combination with chemotherapy for treatment of advanced breast cancer

✍ G.Robustelli Delia Cuna; A. Pellegrini 📂 Article 📅 1983 🏛 Elsevier Science 🌐 English ⚖ 112 KB

High dose, dose-intensive chemotherapy w

High dose, dose-intensive chemotherapy with Doxorubicin and Cyclophosphamide for the treatment of advanced breast cancer

✍ Ferguson, J.E.; Dodwell, D.J.; Seymour, A-M.; Richards, M.A.; Howell, A. 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 169 KB

Phase II study of high dose epirubicin i

Phase II study of high dose epirubicin in combination with cyclophosphamide in patients with advanced breast cancer

✍ Levi, J. A. ;Tattersall, M. H. ;Beith, J. M. ;Bell, D. ;Snyder, R. D. ;Wheeler, 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB

Dose intensification of mitoxantrone in

Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study

✍ Francesco Di Costanzo; Andrea Sdrobolini; Luigi Manzione; Domenico Bilancia; Lui 📂 Article 📅 1999 🏛 Springer US 🌐 English ⚖ 42 KB

Phase I dose escalation study of docetax

Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer

✍ Yeul Hong Kim; Hee Yeon Seo; Yoon Tae Jeen; Hoon-Kyo Kim; Byoung Yong Shim; Jinm 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 296 KB

A phase II study of high-dose medroxypro

A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer

✍ Geoffrey Falkson; Hèndré C. Falkson 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high